Skip to Content

Pexidartinib Disease Interactions

There are 2 disease interactions with pexidartinib:


Pexidartinib (applies to pexidartinib) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Bile Acid Synthesis Disorders, Biliary Obstruction

Pexidartinib can cause serious and potentially fatal liver injury. No dose adjustment of pexidartinib is needed for patients with mild hepatic impairment. Caution should be exercised when using this agent in patients with moderate to severe hepatic impairment as the recommended dose has not been established in these patients. Avoid this drug in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than ULN); or active liver or biliary tract disease, including increased alkaline phosphatase. It is recommended to monitor liver tests before initiation of treatment and at specified intervals during treatment. Withhold and reduce the dose or permanently discontinue pexidartinib based on the severity of hepatotoxicity.


Pexidartinib (applies to pexidartinib) renal Impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Dose modification of pexidartinib is needed for patients with renal impairment. It is recommended to reduce the dose when administering pexidartinib to patients with mild to severe renal impairment (CrCl 15 to 89 mL/min, estimated by Cockcroft-Gault using actual body weight). The recommended dosage is 200 mg in the morning and 400 mg in the evening.

Pexidartinib drug interactions

There are 540 drug interactions with pexidartinib

Pexidartinib alcohol/food interactions

There are 2 alcohol/food interactions with pexidartinib

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.